The application of CGM technology for individuals with T2D on non‐intensive insulin therapy has the potential to significantly enhance their care, and provide primary care teams with the tools to understand day‐to‐day glycaemic health status metrics in greater detail. This evidence concerns the gene INS and type 2 diabetes mellitus.